

Ocular Drug Delivery System

Nikita Jadhav, Ms. Pratiksha Gosavi, Dr. Gajanan Sanap

Department of Pharmacy

LBYP College of Pharmacy, Chhatrapati Sambhajanagar, Maharashtra, India

Abstract: *The projected advent of new medications with short biological half-lives, whose efficacy may depend on a more continuous drug supply than eyedrops can offer, is one reason why innovative ocular drug delivery methods are currently garnering more consideration. moreover due to the possibility for various delivery methods to lessen the negative effects of the Recently released or currently being researched medications with increased potency. certain ophthalmic delivery systems improve corneal absorption to prolong the period of medication activity; These systems include hydrophilic ocular inserts, soluble gels and emulsions, and ion-pair Prodrugs, connections, and liposome. This paper's goal is to review antibiotic formulations intended for ocular delivery. Initially, the ocular barriers and their anatomy and physiology were explained. Topical formulations include contact lenses, ophthalmic inserts, hydrogels, eye drops, and ointments. created in a follow-up section to describe the ocular administration and the presently available quantity format. Lastly, a summary of current developments in the administration of antibiotics to the eyes is given. Not in vivo and Studies conducted in vivo examined the effectiveness of antibacterial compounds. various combinations and configurations are created to lengthen the period of time that antibiotics remain in the eye, enhance their absorption, and the reaction of therapy. The ability to keep the drug at a therapeutic level at the site of action is the greatest obstacle to ocular medicine. In this eye care procedure, illnesses interfere with one's ability to concentrate effectively. This method of delivering drugs to the eyes is hindered by the obstacles that shield the eyes. The active ingredient's bioavailability The main obstacle is the pharmacological substance. Current delivery is optimal for ocular therapies because Comparing the lesser dose needed to the systemic use due to its quick start of action. Topical absorption in this case is this trans-corneal approach to the inner regions of the eye permeation is thought to be the drug's main route of action.*

Keywords: Ophthalmic drug insert, ocular therapy , precorneal.

REFERENCES

- [1]. Thakur RR. Modern Delivery Systems for Ocular Drug Formulations: A Comparative Overview W.R.T Conventional Dosage Form. Int. J. Res. In. Phar & Biomed Sci, 2011; 2 (1): 8-18.
- [2]. Remington, L.A. Clinical anatomy and physiology of the visual system, 3rd ed.; Elsevier/Butterworth Heinemann: St. Louis, MO, USA, 2012; ISBN 978-1-4377-1926-0 .
- [3]. Fujiwara T, Margolis R.; Slakter J.S.; Spaide R.F. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am. J. Ophthalmol. Vol 148, 2009, 445-450.
- [4]. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev, 58, 2006, 1131–35
- [5]. Wilson CG, Zhu YP, Kurmala P, Rao LS, Dhillon B. Ophthalmic drug Delivery. In: Anya M.Hillery, Andrew W.Lloyd James Swabrick (eds.), Drug Delivery and targeting, Taylor and Francis e-library, London, 2005; 298-318.
- [6]. Jtirvinena K, Tomi J, Urttia SA. Ocular absorption following topical delivery. Adv Drug Deliv Rev, 16, 1995, 3-19.
- [7]. <https://www.sciencedirect.com/topics/medicine-and-dentistry/intravitreal-administration> .
- [8]. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release, 122, 2007, 119–34.
- [9]. <https://en.m.wikipedia.org/wiki/Retina>

- [10]. Wilson CG, Zhu YP, Kurmala P, Rao LS, Dhillon B. Ophthalmic drug Delivery. In: Anya M. Hillery, Andrew W. Lloyd James Swabrick (eds.), Drug Delivery and targeting, Taylor and Francis e-library, London, 2005; 298-318
- [11]. Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020;328:895-916. <https://doi.org/10.1016/j.jconrel.2020.10.025>.
- [12]. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. AAPS J. 2010 May 1;12(3):348-60.
- [13]. Van der Bijl P, van Eyk AD, Meyer D, Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea, 2001;20:505-508
- [14]. <https://images.app.goo.gl/tsUUqTFHLG632GsS9>
- [15]. Meqi SA, Deshpande SG. Ocular drug delivery: Controlled and novel drug delivery. New delhi: CBS Publishers; 2002, p 82-84.
- [16]. <https://www.sciencedirect.com/topics/medicine-and-dentistry/intravitreal-administration>
- [17]. Chan KC, Yu Y, Ng SH, Mak HK, Yip YWY, van der Merwe Y, et al. Intracameral injection of a chemically cross-linked hydrogel to study chronic neurodegeneration in glaucoma. Acta Biomater. 2019;94:219-31. <https://doi.org/10.1016/j.actbio.2019.06.005>.
- [18]. Jung JH, Chiang B, Grossniklaus HE, Prausnitz MR. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. J Control Release. 2018;277:14-22. <https://doi.org/10.1016/j.jconrel.2018.03.001>
- [19]. Burgalassi S, Chetoni P, Monti D, Saettone MF, Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines, Toxicol Lett. 2001;122: 1-2.
- [20]. Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016;23(8):3017-26. <https://doi.org/10.3109/10717544.2016.1138342>
- [21]. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug development and industrial pharmacy. 1;39 (11)(2013 Nov) 1599-617. <https://images.app.goo.gl/GpHhwtF4exYUYC367>
- [22]. Gote V, Sikder S, Sicotte J, Pal D. Ocular Drug Delivery: Present Innovations and Future Challenges. Journal of Pharmacology and Experimental Therapeutics. 1 (2019 Jan) j100-119.
- [23]. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura M. Enhancement of ocular penetration. Critical reviews on therapeutic drug carrier systems.
- [24]. Meseurger G, Gurny R, Buri P, Rozier A, Plazonnet B. 1993. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various Ophthalmic formulations containing pilocarpine. International journal of pharmaceutics 1993; 95: 229-234.
- [25]. Gurny, H. Ibrahim and P. Buri, The development and use of insitu formed gels triggered by pH-in biopharmaceutics of ocular drug delivery, Edman, P., CRS PRESS, (1993), pp. 81-90.
- [26]. Nguyen ET, Shorstein NH. Preparation of intracameral antibiotics for injection. J Cataract Refract Surg. 2013;39(11):1778-9. <https://doi.org/10.1016/j.jcrs.2013.08.036>.
- [27]. Heralgi MM, Badami A, Vokuda H, Venkatachalam K. An update on voriconazole in ophthalmology. Of Sci J Delhi Ophthalmol Soc. 2016;27(1):915.
- [28]. Higuchi, T. Ocular Insert. U.S. Patent 3,630,200 A, 28 December 1971.
- [29]. Kumari, A.; Sharma, P.; Garg, V.; Garg, G. Ocular inserts—Advancement in therapy of eye diseases. J. Adv. Pharm. Technol. Res. 2010, 1, 291. [CrossRef] [PubMed]
- [30]. Baranowski, P.; Karolewicz, B.; Gajda, M.; Pluta, J. Ophthalmic drug dosage forms: Characterisation and research methods. Sci. World J. 2014, 2014, 1-14. [CrossRef] [PubMed].
- [31]. Vandamme TF, Microemulsions as ocular drug delivery system: recent development and future challenges. Prog Retin Eye Res, 2002; 21: 15-34.
- [32]. Sampath K, Bhowmik D, Harish G, Duraivel S and kumar P. (2013). Ocular Inserts: A Novel Controlled Drug Delivery System. The Pharma Innovation Journal, 1(12), 1-16.
- [33]. Saettone MF, Salminen L. (2015). Ocular inserts for topical delivery. Advanced Drug Delivery, 16, 95-106.

- [34]. Sahane NK, Banarjee SK, Gaikwad DD, Jadhav SL and Throat RM. (2010). Ocular Inserts- A Review. Drug Invention, 2, 57–64.
- [35]. Duvvuri S, Majumdar S and Mitra AK. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opinion and Biological Therapeutics, 3, 45-56.
- [36]. A Textbook of Novel drug delivery systems by author Dr. Gajanan s.sanap, Ms Pranali P. Hatwar .
- [37]. Lee VH. (2012). Precorneal, Corneal and Postcorneal factors. In: Mitra AK (Ed.). Ophthalmic Drug
- [38]. Keister JC, Cooper ER, Missel PJ, Lang JC and Huger DF.(1991). Limits on optimizing ocular drug delivery. Journal of pharmaceutical sciences, 80, 50-3.
- [39]. <https://images.app.goo.gl/7nn5nK3yEDWepvmh6>
- [40]. Arul kumaran KSG, Karthika K and Padmapreetha J. (2010). Comparative review on conventional and advanced ocular drug delivery formulations, International Journal of Pharmacy and Pharmaceutical Sciences, 2, 1.
- [41]. Lee, S.S.; Hughes, P.M.; Robinson, M.R. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr. Opin. Ophthalmol. 2009; 20: 511-519.
- [42]. Vyas SP, Khar RK, Ed. Targeted and controlled drug delivery, CBS Publishers, New delhi, 2011:374-375.
- [43]. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. *International journal of pharmaceuticals*. 2013;447:75–93. [PMC free article] [PubMed] [Google Scholar]
- [44]. <https://doi.org/10.1016/j.addr.2008.09.002>